Our meta-analysis of a longer PFS but not OS for PD-1 inhibitors in patients with asymptomatic brain metastases does not support previous studies that patients with advanced brain metastasis of NSCLC given with PD-1/PD-L1 inhibitors obtained longer OS (69). This evidence concerns the gene CD274 and non-small cell lung carcinoma.